216 related articles for article (PubMed ID: 25182392)
1. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
Bezniakow N; Gos M; Obersztyn E
Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
[TBL] [Abstract][Full Text] [Related]
2. A review of craniofacial and dental findings of the RASopathies.
Cao H; Alrejaye N; Klein OD; Goodwin AF; Oberoi S
Orthod Craniofac Res; 2017 Jun; 20 Suppl 1(Suppl 1):32-38. PubMed ID: 28643916
[TBL] [Abstract][Full Text] [Related]
3. Autism traits in the RASopathies.
Adviento B; Corbin IL; Widjaja F; Desachy G; Enrique N; Rosser T; Risi S; Marco EJ; Hendren RL; Bearden CE; Rauen KA; Weiss LA
J Med Genet; 2014 Jan; 51(1):10-20. PubMed ID: 24101678
[TBL] [Abstract][Full Text] [Related]
4. RASopathies for Radiologists.
Handa A; Tsujioka Y; Nishimura G; Nozaki T; Kono T; Jinzaki M; Harms T; Connolly SA; Sato TS; Sato Y
Radiographics; 2024 May; 44(5):e230153. PubMed ID: 38602868
[TBL] [Abstract][Full Text] [Related]
5. An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.
Yi JS; Perla S; Bennett AM
Cardiovasc Drugs Ther; 2023 Dec; 37(6):1193-1204. PubMed ID: 35156148
[TBL] [Abstract][Full Text] [Related]
6. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.
Pierpont ME; Magoulas PL; Adi S; Kavamura MI; Neri G; Noonan J; Pierpont EI; Reinker K; Roberts AE; Shankar S; Sullivan J; Wolford M; Conger B; Santa Cruz M; Rauen KA
Pediatrics; 2014 Oct; 134(4):e1149-62. PubMed ID: 25180280
[TBL] [Abstract][Full Text] [Related]
7. The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy.
Pierpont EI; Bennett AM; Schoyer L; Stronach B; Anschutz A; Borrie SC; Briggs B; Burkitt-Wright E; Castel P; Cirstea IC; Draaisma F; Ellis M; Fear VS; Frone MN; Flex E; Gelb BD; Green T; Gripp KW; Khoshkhoo S; Kieran MW; Kleemann K; Klein-Tasman BP; Kontaridis MI; Kruszka P; Leoni C; Liu CZ; Merchant N; Magoulas PL; Moertel C; Prada CE; Rauen KA; Roelofs R; Rossignol R; Sevilla C; Sevilla G; Sheedy R; Stieglitz E; Sun D; Tiemens D; White F; Wingbermühle E; Wolf C; Zenker M; Andelfinger G
Am J Med Genet A; 2024 Apr; 194(4):e63477. PubMed ID: 37969032
[TBL] [Abstract][Full Text] [Related]
8. Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework.
Grant AR; Cushman BJ; Cavé H; Dillon MW; Gelb BD; Gripp KW; Lee JA; Mason-Suares H; Rauen KA; Tartaglia M; Vincent LM; Zenker M
Hum Mutat; 2018 Nov; 39(11):1485-1493. PubMed ID: 30311384
[TBL] [Abstract][Full Text] [Related]
9. Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes.
Papadopoulou A; Bountouvi E
Front Endocrinol (Lausanne); 2023; 14():1231828. PubMed ID: 37964950
[TBL] [Abstract][Full Text] [Related]
10. New prospectives on treatment opportunities in RASopathies.
Gelb BD; Yohe ME; Wolf C; Andelfinger G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):541-560. PubMed ID: 36533679
[TBL] [Abstract][Full Text] [Related]
11. The Cardiofaciocutaneous Syndrome: From Genetics to Prognostic-Therapeutic Implications.
Scorrano G; David E; Calì E; Chimenz R; La Bella S; Di Ludovico A; Di Rosa G; Gitto E; Mankad K; Nardello R; Mangano GD; Leoni C; Ceravolo G
Genes (Basel); 2023 Nov; 14(12):. PubMed ID: 38136934
[TBL] [Abstract][Full Text] [Related]
12. RASopathies - what they reveal about RAS/MAPK signaling in skeletal muscle development.
Rauen KA; Tidyman WE
Dis Model Mech; 2024 Jun; 17(6):. PubMed ID: 38847227
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans.
Gualtieri A; Kyprianou N; Gregory LC; Vignola ML; Nicholson JG; Tan R; Inoue SI; Scagliotti V; Casado P; Blackburn J; Abollo-Jimenez F; Marinelli E; Besser REJ; Högler W; Karen Temple I; Davies JH; Gagunashvili A; Robinson ICAF; Camper SA; Davis SW; Cutillas PR; Gevers EF; Aoki Y; Dattani MT; Gaston-Massuet C
Nat Commun; 2021 Apr; 12(1):2028. PubMed ID: 33795686
[TBL] [Abstract][Full Text] [Related]
14. Cardio
Chen B; Chen S; Xiong J; Yin F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Apr; 46(4):432-437. PubMed ID: 33967092
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic perspectives in Noonan syndrome and RASopathies.
Saint-Laurent C; Mazeyrie L; Yart A; Edouard T
Eur J Pediatr; 2024 Mar; 183(3):1011-1019. PubMed ID: 37863846
[TBL] [Abstract][Full Text] [Related]
16. Cancer incidence and surveillance strategies in individuals with RASopathies.
Ney G; Gross A; Livinski A; Kratz CP; Stewart DR
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):530-540. PubMed ID: 36533693
[TBL] [Abstract][Full Text] [Related]
17. Divergent effects of intrinsically active MEK variants on developmental Ras signaling.
Goyal Y; Jindal GA; Pelliccia JL; Yamaya K; Yeung E; Futran AS; Burdine RD; Schüpbach T; Shvartsman SY
Nat Genet; 2017 Mar; 49(3):465-469. PubMed ID: 28166211
[TBL] [Abstract][Full Text] [Related]
18. Unilateral segmental presentation and a novel EPHB4 gene variant in capillary malformation-arteriovenous malformation type 2.
Valente C; Caldeira MB; Duarte B; Batista J; Cordeiro AI
Pediatr Dermatol; 2024; 41(2):344-345. PubMed ID: 38092051
[TBL] [Abstract][Full Text] [Related]
19. Noonan syndrome - a new survey.
Tafazoli A; Eshraghi P; Koleti ZK; Abbaszadegan M
Arch Med Sci; 2017 Feb; 13(1):215-222. PubMed ID: 28144274
[TBL] [Abstract][Full Text] [Related]
20. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.
Tartaglia M; Gelb BD
Ann N Y Acad Sci; 2010 Dec; 1214():99-121. PubMed ID: 20958325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
